In Search of NeuroSearch
Executive Summary
Recent clinical failures have left Denmark's NeuroSearch uncomfortably dependent on NS2330, a promising phase II Alzheimer's and Parkinson's treatment out-licensed to Boehringer Ingelheim. To reduce risk, NeuroSearch will have to partner its remaining research programs earlier.